Business Description
argenx SE
NAICS : 541714
SIC : 2834
ISIN : NL0010832176
Total Employee Number:
1,863Compare
Compare
Traded in other countries / regions
ARGX.BelgiumARGX.USA0QW0.UKA1RG34.BrazilARGXN.MexicoARGX.Austria1AE.Germany IPO Date
2015-03-27Description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 94.15 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.03 | |||||
Interest Coverage | 320.34 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 27.54 | |||||
Beneish M-Score | -1.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 96 | |||||
3-Year Book Growth Rate | 28.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 32.84 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 26.86 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 99.99 | |||||
9-Day RSI | 98.83 | |||||
14-Day RSI | 93.49 | |||||
3-1 Month Momentum % | 24.29 | |||||
6-1 Month Momentum % | 8.34 | |||||
12-1 Month Momentum % | 61.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.23 | |||||
Quick Ratio | 4.87 | |||||
Cash Ratio | 3.36 | |||||
Days Inventory | 314.17 | |||||
Days Sales Outstanding | 92.03 | |||||
Days Payable | 364.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.8 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.47 | |||||
Operating Margin % | 28.08 | |||||
Net Margin % | 31.91 | |||||
EBITDA Margin % | 32.32 | |||||
FCF Margin % | 12.3 | |||||
OCF Margin % | 14.7 | |||||
ROE % | 22.84 | |||||
ROA % | 19.6 | |||||
ROIC % | 43.51 | |||||
3-Year ROIIC % | 67.34 | |||||
ROC (Joel Greenblatt) % | 164.07 | |||||
ROCE % | 22.99 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 41.41 | |||||
Forward PE Ratio | 34.97 | |||||
PE Ratio without NRI | 42.38 | |||||
PS Ratio | 13.22 | |||||
PB Ratio | 7.91 | |||||
Price-to-Tangible-Book | 8.22 | |||||
Price-to-Free-Cash-Flow | 107.82 | |||||
Price-to-Operating-Cash-Flow | 90.25 | |||||
EV-to-EBIT | 35.45 | |||||
EV-to-Forward-EBIT | 25.93 | |||||
EV-to-EBITDA | 35.45 | |||||
EV-to-Forward-EBITDA | 25.58 | |||||
EV-to-Revenue | 11.46 | |||||
EV-to-Forward-Revenue | 8.69 | |||||
EV-to-FCF | 93.68 | |||||
Price-to-GF-Value | 0.65 | |||||
Price-to-Projected-FCF | 51.59 | |||||
Price-to-Median-PS-Value | 0.36 | |||||
Price-to-Graham-Number | 4.27 | |||||
| Price-to-Net-Current-Asset-Value | 10.46 | |||||
| Price-to-Net-Cash | 18.81 | |||||
Earnings Yield (Greenblatt) % | 2.82 | |||||
FCF Yield % | 0.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ARGNF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
argenx SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4,661.482 | ||
| EPS (TTM) ($) | 22.5 | ||
| Beta | -0.4247 | ||
| 3-Year Sharpe Ratio | 0.77 | ||
| 3-Year Sortino Ratio | 1.45 | ||
| Volatility % | 36.66 | ||
| 14-Day RSI | 93.49 | ||
| 14-Day ATR ($) | 5.204098 | ||
| 20-Day SMA ($) | 907.345 | ||
| 12-1 Month Momentum % | 61.61 | ||
| 52-Week Range ($) | 547.6 - 960.58 | ||
| Shares Outstanding (Mil) | 62.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
argenx SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
argenx SE Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-22 | In 104 days | ||
| Third quarter earnings results for 2026 | 2026-10-22 | In 104 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-23 | In 13 days | ||
| Second quarter earnings results for 2026 | 2026-07-23 | In 13 days | ||
| R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis | 2026-06-23 14:00 | 900.00 (+0.00%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 16:00 | 885.00 (+0.00%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-03 12:40 | 835.00 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-12 10:40 | 803.19 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 803.19 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 803.19 (+0.00%) |
Show
Entries
argenx SE Frequently Asked Questions
What is argenx SE(ARGNF)'s stock price today?
The current price of ARGNF is $935.38. The 52 week high of ARGNF is $960.58 and 52 week low is $547.60.
When is next earnings date of argenx SE(ARGNF)?
The next earnings date of argenx SE(ARGNF) is 2026-07-23.
Does argenx SE(ARGNF) pay dividends? If so, how much?
argenx SE(ARGNF) does not pay dividend.
Guru Commentaries on OTCPK:ARGNF
No articles.
Press Release
Articles on argenx SE
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers